Price movement over the last 24 hours
Agilent Technologies Inc vs Synchrony Financial — how do they compare? Agilent Technologies Inc trades at $129.06 (market cap $37.04B), while Synchrony Financial trades at $71.32 (market cap $25.40B). The key difference: Agilent Technologies Inc is the larger of the two by market cap, and Synchrony Financial pays the higher dividend (1.59%). Which is the better fit depends on your goals.
| A | SYF | |
|---|---|---|
Market Cap | $37.04B | $25.40B |
Sector | Health | Financials |
52-Week High | $157.20 | $88.47 |
52-Week Low | $110.24 | $63.78 |
Enterprise Value | $38.59B | — |
Dividend Yield | 0.78% | 1.59% |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
SYF trades at $77.05, up 0.94% today, with a bullish technical outlook supported by moving averages and key resistance at $78. The stock shows strong fundamentals with a P/E of 7.98, net income margin of 24.06%, and consistent earnings beats in recent quarters. Recent news highlights executive changes and partnership expansions, reinforcing growth initiatives.
The outlook remains positive with a consensus price target of $85, representing ~10% upside. Risks include interest rate sensitivity and competitive pressures, but strong analyst buy ratings (62.5%) and robust cash flow support a favorable investment case for value-oriented investors seeking financial sector exposure.
Trailing returns across standard periods
Latest headlines on both assets
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →